PDF herunterladen
CC BY-NC-ND 4.0 · South Asian J Cancer 2020; 09(01): 06-12
DOI: 10.4103/sajc.sajc_157_19
Letter to the Editor

An exceptional response to olaparib in relapsed and refractory BRCA2 mutated non-small cell lung cancer in hereditary breast–ovarian cancer syndrome

Vikas T. Talreja
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra
,
Vanita Noronha
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra
,
Amit Joshi
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra
,
Vijay Patil
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra
,
Kumar Prabhash
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra
› Institutsangaben Financial support and sponsorship: Nill.
› Weitere Informationen
Auch verfügbar auf
  als PDF herunterladen Lizenzen und Reprints


Publikationsverlauf

Artikel online veröffentlicht:
14. Dezember 2020

© 2020. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012;366:1382-92.
  • 2 Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: A phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011;12:852-61.
  • 3 O'Sullivan CC, Moon DH, Kohn EC, Lee JM. Beyond breast and ovarian cancers: PARP inhibitors for BRCA mutation-associated and BRCA-like solid tumors. Front Oncol 2014;4:42.
  • 4 Alexandrov LB, Stratton MR. Mutational signatures: The patterns of somatic mutations hidden in cancer genomes. Curr Opin Genet Dev 2014;24:52-60.
  • 5 Wainberg ZA, Rafii S, Ramanathan RK, Mina LA, Byers LA, Goldman RC, et al. Safety and antitumor activity of the PARP inhibitor BMN673 in a phase 1 trial recruiting metastatic small-cell lung cancer (SCLC) and germline BRCA-mutation carrier cancer patients [abstract]. J Clin Oncol. 2014;32(5s). Abstract 7522.
  • 6 Owonikoko TK, Dahlberg SE, Sica GL, Wagner LI, Wade JL 3rd, Srkalovic G, et al. Randomized phase II trial of cisplatin and etoposide in combination with veliparib or placebo for extensive-stage small-cell lung cancer: ECOG-ACRIN 2511 Study. J Clin Oncol 2019;37:222-9.
  • 7 Molife LR, Roxburgh P, Wilson RH, Gupta A, Middleton MR, Michie TR, et al. A phase I study of oral rucaparib in combination with carboplatin.10.1200/jco.2013.31.15_suppl.2586 Journal of Clinical Oncology 2013;31:2586.
  • 8 Rajan A, Carter CA, Kelly RJ, Gutierrez M, Kummar S, Szabo E, et al. Aphase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors. Clin Cancer Res 2012;18:2344-51.
  • 9 Appleman LJ, Beumer JH, Jiang Y, Puhalla S, Lin Y, Ramalingam TK, et al. A phase I study of veliparib (ABT- 888) in combination with carboplatin and paclitaxel in advanced solid malignancies. 10.1200/jco.2012.30.15_suppl.3049 Journal of Clinical Oncology 2012;30:3049.
  • 10 A Randomised Phase II Trial of Olaparib Maintenance Versus Placebo Monotherapy in Patients with Chemosensitive Advanced Non-Small Cell Lung Cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT01788332. [Last accesed on 2019 Apr 24].